How much does a box of macitentan cost after it is included in medical insurance? List of policy implementation areas

Macitentan (macitentan), as an important drug for the treatment of pulmonary arterial hypertension, has been approved for marketing in China, and the original drug has been included in the scope of medical insurance. This means that patients who meet the conditions for medical insurance can enjoy a certain proportion of reimbursement, reducing the burden of treatment costs. The common specifications are 10mg*30 tablets. Each box sells for about more than 3,000 yuan. The specific price may fluctuate due to regional differences and different hospital procurement channels.

In addition to original drugs, domestic macitentan drugs have also been launched on the domestic market. These domestic drugs are usually more affordable and easier for patients with long-term treatment of pulmonary arterial hypertension to afford. Domestic drugs have undergone strict supervision in terms of efficacy, quality and ingredients, and can achieve similar efficacy to original drugs in clinical use, providing patients with more choices.

In terms of policy implementation, macitentan, which is currently included in medical insurance, can be reimbursed in most first-tier cities and provinces. The specific reimbursement ratio and policy details will vary according to the regulations of local medical insurance bureaus. Patients should consult the local hospital pharmacy or medical insurance window before use to learn about the latest policy implementation and actual reimbursement amounts, so as to better arrange treatment plans and financial budgets.

In overseas markets, macitentan is also available as original medicine and generic drugs, such as 10mg*30 tablets produced by Laos Pharmaceutical Factory, with a price of about more than 300 yuan per box (may fluctuate due to exchange rates). Overseas generic drugs are basically the same as the original drugs in terms of ingredients and clinical efficacy, providing an alternative for patients who cannot obtain drugs through domestic medical insurance channels.

Keyword tags:

Macitentan, price after medical insurance, policy implementation, reimbursement ratio, regional differences, domestic drugs, original drugs, economic burden

Reference materials:https://www.drugs.com/